TOP10 sales in Beijing, Shanghai and Guangzhou are released!

Thanks to the concentration of high-quality medical resources, the three cities of Beijing, Shanghai, and Guangzhou have always been the “big households” of domestic drug sales

2021H1 Beijing, Shanghai, and Guangzhou public hospitals terminal chemical drug city layout (unit: 100 million yuan)

Source: Mi Nei.

Beijing: Lipitor's "hard carry", lung cancer star drug plummets by 15%

Annual sales trend of terminal chemical drugs in Beijing public hospitals (unit: 100 million yuan)

Source: Mi Nei.

According to data from Mi Nei.

2021H1 Beijing Public Hospital Top 10 Chemical Drug Brands

Source: Mi Nei.

In the TOP10 brand, there are 6 anti-tumor drugs, and 1 systemic antibacterial drug, antithrombotic drug, blood substitute and perfusion fluid, and blood lipid regulator

Meropenem for injection, which ranks first on the list, is a carbapenem antibiotic.

Pfizer's Lipitor (Atorvastatin calcium) stubbornly held the third place

AstraZeneca's Teresa (osimertinib mesylate tablets) 2021H1 sales fell 14.

Shanghai: PPI injections soared 467%! Livzon, Yangtze River, Sansheng on the list

Annual sales trend of terminal chemical drugs in Shanghai public hospitals (unit: 100 million yuan)

Source: Mi Nei.

According to data from Mi Nei.

2021H1 Shanghai Public Hospital's Top 10 Chemical Drug Brands

Source: Mi Nei.

Among the TOP10 brands, there are 4 anti-tumor drugs, and 2 plasma substitutes and infusions

Sanofi's leroxatin (oxaliplatin for injection) ranked first, with sales in 2021H1 increasing by 107.

Ilaprazole is a proton pump inhibitor and is currently the strongest class of drugs that inhibit gastric acid secretion

In addition to Livzon Group’s ilaprazole sodium for injection, the domestic brands on the list include Yangtze River Pharmaceutical’s Dezocine Injection, and 3SBio’s Terpio (recombinant human thrombopoietin injection)

Guangzhou: Sales of breast cancer "magic medicine" soared by 120%! Qilu and Shiyao are on the list

Annual sales trend of terminal chemical drugs in public hospitals in Guangzhou (unit: 100 million yuan)

Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals

According to data from Mi Nei.
com, the terminal chemical drug sales of public hospitals in Guangzhou in 2021H1 are close to 10 billion yuan, a year-on-year increase of 17.
07% and a year-on-year decline of more than 10%
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, blood and hematopoietic system drugs, accounting for 31.
79%, 13.
82%, and 12.
44% respectively
.

2021H1 Guangzhou Public Hospital Terminal Chemical Drug Brand Top 10

Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals

Among the TOP10 brands, there are 6 anti-tumor drugs, and 1 systemic antibacterial drug, hemostatic drug, blood substitute and perfusion fluid, and immunostimulant
.
The TOP5 brands are all anti-tumor drugs, and the sales of Sanofi’s oxaliplatin and AstraZeneca’s osimertinib both exceeded 100 million yuan
.
Roche still has 3 monoclonal antibodies on the list, the difference is that Pertuzumab replaced rituximab
.

Roche's breast cancer targeted drug Pattuzumab (Pertuzumab injection) squeezed into the TOP10 for the first time, and sales in 2021H1 increased by 122.
65% year-on-year
.
Pertuzumab is a second-generation targeted drug for HER2-positive breast cancer.
It was approved for marketing in China at the end of 2018 and entered the National Medical Insurance Negotiation List at the end of 2019.
The price is 4955 yuan per tube (420mg/14ml), which is more included in medical insurance.
Compared with the previous 18,800 yuan/branch, a decrease of 74%
.
Medical insurance negotiations have promoted the rapid increase in volume of this product.
In 2020, the sales of Pertuzumab in public hospitals in Guangzhou will increase by more than 4200%
.

The domestic brands on the list include Qilu Pharmaceutical's Xinruibai (pegylated recombinant human granulocyte stimulating factor injection), and CSPC Ouyi's Domesu (doxorubicin hydrochloride liposome injection)
.

Pegylated recombinant human granulocyte stimulating factor injection is a long-acting baiyao.
According to data from Meinenet, the domestic long-acting baiyao market has continued to rise in recent years.
Currently, the product manufacturers include Qilu Pharmaceutical and CSPC.
, Hengrui Pharmaceutical, and New Times Pharmaceutical
.

Doxorubicin hydrochloride is an anthracycline antibiotic and a broad-spectrum anti-tumor drug.
It is mainly used for chemotherapy of multiple myeloma, lymphoma, ovarian cancer, and breast cancer
.
Doxorubicin Hydrochloride Liposome Injection is a high-end nano-preparation, and currently only three domestic companies have been approved for production, including CSPC Ouyi, Changzhou Jinyuan Pharmaceutical and Fudan Zhangjiang
.
Among them, CSPC Ouyi is the first company that has reviewed this product
.